Hardly any "retail" would have got any. Was not an open IPO.
Those who mentioned CYP, that first run was on GMP where the cells were proven to be manufactured at a scalable level safely.
Stock ran from 39-40c to $1.44. (and all the way back once punters realized you still need human trials)
EX1 are wanting to also get to GMP soon, so this could be a big catalyst 2019. EX1 also have about the same SOI as CYP at same stage.
The big advantage for Exopharm, is the "juice" (good stuff) from the cell itself can be extracted with the LEAP technology, and the advantage there is transportation and delivery (cells need freezing)....so I would say EX1 is looking to be a GEN 3 technology in the rapidly developing stem cell therapy market.
GEN 1 being bone marrow harvesting (MSB)
CYP (GEN 2) has been the best performing Biotech in this MCap starting category ($10-$50m) over last 2.5 years at 232% (max over 400%) and holding.
Might give you some idea where this can go given founder and technology.
EX1 Price at posting:
43.0¢ Sentiment: Buy Disclosure: Held
